Phase I, 5-period, open-label study evaluating potential drug–drug interactions between ceftolozane/tazobactam and drugs metabolised by CYP1A2 or CYP3A4 or transported by organic anion transporters OAT1 and OAT3 in healthy volunteers

Trial Profile

Phase I, 5-period, open-label study evaluating potential drug–drug interactions between ceftolozane/tazobactam and drugs metabolised by CYP1A2 or CYP3A4 or transported by organic anion transporters OAT1 and OAT3 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2015

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Caffeine; Furosemide; Midazolam
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top